INNIO
23.6.2022 10:32:13 CEST | Business Wire | Press release
INNIO, a leading energy solution and service provider, has published its Sustainability Report for 2021 Together Towards Zero , which defines the company’s performance in meeting environmental, social, and governance (ESG) goals. While INNIO is currently empowering industries and communities to transition to net zero, this report – prepared in accordance with GRI and SASB standards – formally communicates on progress and sustainability-related performance providing, transparency about how INNIO is contributing to a green tomorrow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005974/en/
Earlier this year, Sustainalytics ranked INNIO number one out more than 500 companies, meaning it has the lowest risk within the machinery industry assessed (Rating of 11 “Low risk level”). In addition, INNIO received the Gold Medal from EcoVadis, placing its Jenbacher business in the top 1% of industry peers. Last year, INNIO became signatory of the Science Based Targets initiative and the United Nations ‘Race to Zero’ campaign, that brings together global leadership for a healthy, resilient, and zero-carbon future.
In accordance with global frameworks and commitments, INNIO set out ambitious sustainability targets in three strategic focus areas where it sees the most material impacts and opportunities for improvement: Low Carbon and Circular Products , Resilient Supply Chain and Manufacturing , and Responsible Operations and Social Responsibility .
Selected key ambitions in these areas include:
- Since 2022, INNIO offers all new engines with a “Ready for H2” option. These models can operate with up to 20% vol. hydrogen1 , and can be retrofitted to 100% H2 operation in the future. All Type 4 series engines are offered for 100% H2 operations. As of 2025 and beyond, the entire Jenbacher product line is expected to be rolled out with 100% hydrogen operation.
- Suppliers covering 80% of direct and indirect spend must commit to net zero by 2050.
- 50% reduction in Scope 1 and Scope 2 GHG emissions in supply chain and manufacturing (vs. the 2020 base) will be fully implemented by 2030.
- By 2025, identified diversity groups will increase by 25% across functions compared to the 2020 baseline. Diverse people leadership will be developed further by 20302 .
Dr. Olaf Berlien, chief executive officer at INNIO, states:
“I’m incredibly proud of the steps we have taken to implement our ESG strategy. The outstanding recognition we have received for our achievements with leading ESG ratings shows that we are on the right track on our path to net zero.”
Marcin Kawa, vice president Sustainability at INNIO, states:
“INNIO’s 2021 Sustainability Report summarizes a year filled with sustainability and ESG initiatives, collaboration, and progress. “This report is the next milestone in our journey as we move ‘Together Towards Zero.’ I’m happy to be part of a team that is so passionate about making a difference while building transparency and trust among our stakeholders worldwide.”
* Rating took place in February 2022
About INNIO’s 2021 Sustainability Report
INNIO’s 2021 Sustainability Report is a non-financial disclosure published annually. This 2021 disclosure was prepared in accordance with the standards of the Global Reporting Initiative (GRI) core option and the Sustainability Accounting Standards Board (SASB). It also includes an initial analysis in line with the Task Force on Climate-related Financial Disclosures (TCFD) Recommendations Framework. The report also serves as Communication on Progress (COP) for the UN Global Compact (UNGC). Through non-financial reporting, INNIO describes its management and performance of environmental, social, and governance (ESG) issues. INNIO’s disclosures focus on the topics that have been deemed most material to the business based on a materiality assessment. INNIO’s alignment with the United Nations Sustainable Development Goals (UN SDGs) is based on the GRI and the UNGC’s Business Reporting on the UN SDGs. This Sustainability Report has been externally assured. The data presented in the report is consolidated at Group level and covers 100% of business operations and 90% of global locations. This boundary applies to all material topics, unless clearly indicated otherwise. All the health, safety, and environmental data, including greenhouse gas (GHG) data for Scope 1, Scope 2, and Scope 3, cover the INNIO Group using the financial control approach.
For more information, access INNIO’s Sustainability Report 2021 here .
About INNIO
INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, INNIO offers innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. We are individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we are enabling our customers to manage the energy transition along the energy value chain wherever they are in their transition journey.
INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 3,500 experts provides life-cycle support to the more than 54,000 delivered engines globally through a service network in more than 80 countries.
INNIO’s ESG Risk Rating places it number one of more than 500 worldwide companies in the Machinery industry assessed by Sustainalytics.
For more information, visit INNIO’s website at www.innio.com . Follow INNIO on Twitter and LinkedIn .
1
Defined in accounting protocol as either sold with the capacity to run on 100% hydrogen or that can be upgraded at a reasonable cost
2
We will focus on distinct employee groups and diversity dimensions (age, gender, nationality, and minorities) when implementing diversity initiatives. For more information, please visit page 78 in our report.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005974/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
